SURMOUNT-MAINTAIN: what a lower tirzepatide dose actually does to weight maintenance

SURMOUNT-MAINTAIN (The Lancet, May 2026) found that stepping down to 5 mg tirzepatide maintained most weight loss compared to full regain on placebo. Here's what the data actually show.

One of the most common questions people have after losing weight on a GLP-1 medication is whether they can eventually take less of it — or stop entirely — without regaining everything. For tirzepatide (Zepbound), that question had no rigorous trial-based answer until now.

SURMOUNT-MAINTAIN, published May 12, 2026 in The Lancet, is the first dedicated randomized controlled trial to test whether reducing tirzepatide from the maximum tolerated dose to 5 mg can maintain weight loss. The results are meaningful, but they require context to interpret correctly.

The trial asked a focused question: among people who had already lost weight on tirzepatide, what happens when you reduce the dose?

Investigators enrolled 441 adults in the US. All participants first completed a 60-week open-label weight loss period on once-weekly subcutaneous tirzepatide. Participants had a BMI of at least 30 kg/m², or BMI ≥27 with one or more weight-related comorbidities. The mean starting body weight was 113.8 kg, mean BMI 40.1, and median duration of obesity was 13 years.

After the open-label period, 378 participants who had lost at least 5% of their body weight and could tolerate at least 10 mg tirzepatide were randomized 3:3:2 to: continue at maximum tolerated dose (MTD, either 10 or 15 mg; n=140), reduce to 5 mg tirzepatide (n=144), or switch to placebo (n=94). All participants received ongoing lifestyle interventions throughout the 112-week trial.

The mean age was 47 years, 65% were women, most (67%) were White, and participants were all US residents. Nearly all had obesity without type 2 diabetes.

This matters for interpreting applicability. The trial excluded people who couldn't tolerate at least 10 mg tirzepatide — so the study population represents those who were on higher doses before stepping down, not those who stopped due to side effects.

At 112 weeks, the primary endpoint was percent change in body weight from baseline:

• Tirzepatide MTD: −21.9%
• Tirzepatide 5 mg: −16.6%
• Placebo: −9.9%

The estimated treatment differences compared to placebo were −12.0 percentage points for MTD and −6.6 percentage points for 5 mg (both p<0.0001).

On weight regain specifically: only 8% in the MTD group and 25% in the 5 mg group regained at least 50% of what they had previously lost, compared to 67% in the placebo group. Participants who did regain ≥50% of their prior loss were eligible for rescue tirzepatide starting at week 24, so some placebo participants received tirzepatide later in the trial.

The placebo arm in SURMOUNT-MAINTAIN is not a "no treatment" arm in the usual sense. All placebo participants had already achieved significant weight loss on tirzepatide, then had the drug withdrawn. The 67% rate of ≥50% weight regain in that group illustrates what typically happens when GLP-1 therapy stops — and reinforces why the question of maintenance strategies matters clinically.

The placebo results should not be read as "what happens when you stop tirzepatide in general." They reflect average outcomes in people who had achieved substantial weight loss and then stopped the drug entirely.

SURMOUNT-MAINTAIN provides the first specific randomized evidence that 5 mg tirzepatide can meaningfully preserve weight loss compared to stopping the drug. The editorial accompanying the Lancet paper noted: "The clinical rationale for continuing pharmacotherapy at the lowest effective dose for weight maintenance has been acknowledged, but without specific evidence for low-dose regimens — individualized approaches and further research have been called for. SURMOUNT-MAINTAIN now provides information on the effect of dose reduction on the maintenance of bodyweight reduction for the first time in a dedicated RCT."

That said, several things this trial cannot tell you:

• Whether the 5 mg step-down will work as well for someone who couldn't tolerate higher doses at baseline
• What will happen to you as an individual (trial data are averages)
• Whether there's a dose below 5 mg that can also maintain weight loss
• How long 5 mg maintenance needs to continue, or what happens if it's eventually stopped

SURMOUNT-MAINTAIN does not answer what happens if tirzepatide is stopped completely after the 5 mg maintenance period. It doesn't test whether starting tirzepatide at 5 mg (rather than stepping down from a higher dose) produces similar outcomes. Long-term data beyond 112 weeks are not available from this trial. Who the ideal candidate for a step-down approach is — beyond basic inclusion criteria — remains a clinical judgment.

• Based on SURMOUNT-MAINTAIN, am I a reasonable candidate for stepping down to a lower dose?
• What would you want to monitor during and after a dose change?
• What would trigger going back to my previous dose if I do step down?
• Would I still qualify for my current dose if I needed to return to it?

• Body weight at consistent intervals — monthly is reasonable for most
• Appetite and food noise — any notable return may be an early indicator worth raising with your prescriber
• Cardiometabolic markers your clinician tracks: fasting glucose, blood pressure, lipids
• Side effects: the 5 mg group had lower incidence than the MTD group, but GI effects remain the most common at both doses

SURMOUNT-MAINTAIN gives prescribers and patients the first randomized data on tirzepatide step-down dosing. That evidence is useful — it means the conversation can now be grounded in actual trial outcomes, not speculation.

But the data describe averages across a specific trial population. Whether a step-down to 5 mg is right for you depends on your history, tolerability, goals, and what your prescriber sees in your clinical picture. The right time to have this conversation is before you reach your goal weight — not after — so you and your prescriber have more options and more time to plan.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet, published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2. thelancet.com
• American College of Cardiology journal scan summary, May 2026. acc.org